This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by TUCKER, H. ST. G. Articles by BLACKARD, W. G. Search for Related Content PubMed PubMed Citation Articles by TUCKER, H. ST. G. Articles by BLACKARD, W. G.

Persistent Defect in Regulation of Prolactin Secretion after Successful Pituitary Tumor Removal in Women with the Galactorrhea-Amenorrhea Syndrome^*

Division of Endocrinology, Department of Medicine, Virginia Commonwealth University, Medical College of Virginia Richmond, Virginia 23298

Address requests for reprints to: Dr. H. St. George Tucker, Medical College of Virginia, Virginia Commonwealth University, MCV Station, Richmond, Virginia 23298.

TRH, metoclopramide (MCP), chlorpromazine (CPZ), and insulin (ITT) stimulation tests of PRL secretion were carried out in age-matched controls and before and after successful removal of pituitary prolactinomas in women with the galactorrhea-amenorrhea syndrome. In preoperative patients there was a blunted or absent PRL response to TRH in 87%, to MCP in 100%, to CPZ in 100%, and to ITT in 93%. Two to 6 months after successful tumor removal, serum PRL rose 2-fold (the usual criterion for a normal response) in 73% after TRH, in 100% after MCP, but in only 13% after CPZ and in only 14% on ITT. However, the PRL increment with all four tests was significantly lower than that in normal controls. One to 8 yr after successful surgery, the PRL increments after TRH and MCP were returning to normal, but the PRL responses to CPZ and ITT remained blunted. GH, ACTH, and TSH reserves were intact in all patients. The diminished PRL response to all stimulation tests observed up to 6 months postoperatively might be explained by the persistence of a negative feedback effect from high PRL levels associated with the tumor. The more persistent impairment of the PRL response to CPZ and ITT is unexplained but suggests a hypothalamic defect.

^* This work was supported by NIH Grant AMOl-RR-65.

Received April 4, 1980.

This article has been cited by other articles:

				E. F. Rodman, M. E. Molitch, K. D. Post, B. J. Biller, and S. Reichlin Long-term Follow-up of Transsphenoidal Selective Adenomectomy for Prolactinoma JAMA, August 17, 1984; 252(7): 921 - 924. [Abstract] [PDF]

				R. F. Spark, R. Baker, D. C. Bienfang, and R. Bergland Bromocriptine Reduces Pituitary Tumor Size and Hypersecretion: Requiem for Pituitary Surgery? JAMA, January 15, 1982; 247(3): 311 - 316. [Abstract] [PDF]

				H. ST. G. TUCKER, S. R. GRUBB, J. P. WIGAND, A. TAYLON, H. V. LANKFORD, W. G. BLACKARD, and D. P. BECKER Galactorrhea-Amenorrhea Syndrome: Follow-up of Forty-Five Patients After Pituitary Tumor Removal Ann Intern Med, March 1, 1981; 94(3): 302 - 307. [Abstract] [PDF]